Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Physiopathological Roles of p2x Receptors in the Central Nervous System.
Immunomodulatory effects of Vitamin D in multiple sclerosis.
RILUTEK®
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Ustekinumab.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Generic interferon-beta
HL-A antigens and multiple sclerosis.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Gustatory Dysfunction in Multiple Sclerosis
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg

Pages